A method for the treatment of liver fibrosis
- 专利权人:
- ИНК. (US);ХЕМОЦЕНТРИКС
- 发明人:
- МИАО Женхуа (US),ЧАРО Израел (US)
- 申请号：
- RU2018145459
- 公开号：
- RU2018145459A
- 申请日:
- 2017.06.02
- 申请国别(地区):
- RU
- 年份:
- 2020
- 代理人:
- 摘要：
- A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- PHARMACEUTICAL COMPOSITION COMPRISING RESVERATROL DERIVATIVES AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING LIVER CIRRHOSIS OR FIBROSIS
- PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS HEPATIC FIBROSIS AND HEPATIC CIRRHOSIS COMPRISING FUSION PROTEINS
- PHARMACEUTICAL COMPOSITION AND HEALTH FOOD FOR LIVER FIBROSIS, CIRRHOSIS and HEPATITIS
- COMPOSITION FOR PREVENTION AND TREATMENT OF LIVER FIBROSIS OR LIVER CIRRHOSIS COMPRISING OF MESENCHYMAL STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS AS AN ACTIVE INGREDIENT
- COMPOSITION FOR PREVENTING AND TREATING LIVER FIBROSIS OR LIVER CIRRHOSIS, CONTAINING, AS ACTIVE INGREDIENT, MESENCHYMAL STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
